Illustrative image – not actual.Sun Pharma’s wholly-owned US subsidiary, Caraco Pharmaceutical Laboratories, has entered into a definitive agreement with Takeda Pharmaceuticals, USA (a wholly-owned subsidiary of Takeda), to acquire non-Colcrys (colchicine, USP) URL Pharma, Inc. generic business.
As per the agreement, Takeda will retain the ownership of Colcrys and is exclusively responsible for its marketing and promotion. Upon completion of the sale, the non-Colcrys assets of URL Pharma will be owned and managed by Caraco. The deal is subject to satisfaction of customary closing conditions, including applicable regulatory approvals.
During November 2012, Sun Pharma had entered into an agreement to acquire DUSA, a US-based dermatology company, for about $230 million (approx. Rs 1,200 crore).
